Apixaban in Obese Patients

Please use landscape view or desktop screen to view the content.

Characteristic	BMI <30 kg/m² (n = 296)	BMI ≥50 kg/m² (n = 299)	P value*
HAS-BLED score, median (IQR)	2 (1-2)	2 (1-2)	.665
DOAC, n (%) Rivaroxaban Apixaban	67 (23) 229 (77)	118 (39) 181 (61)	<.001 <.001
Prior warfarin use, n (%)	11 (4)	32 (11)	.005
Concomitant aspirin use, n (%)	98 (33)	106 (35)	.847
Concomitant P2Y₁₂ inhibitor use, n (%)	27 (9)	30 (10)	.361
Concomitant NSAIDs use, n (%)	3 (1)	17 (6)	.006
Years of follow-up, median (IQR)	2.01 (1.36-2.05)	2.88 (1.93-4.41)	<.001
Insurance status, n (%) Medicare/Medicaid Commercial Military None/Unknown	218 (74) 73 (24) 2 (1) 2 (1)	206 (69) 84 (28) 4 (1) 4 (1)	.394 - - - -

*To compare patients with a BMI ≥50 kg/m² and those with a BMI 18 to 30 kg/m², the Wilcoxon rank sum test was used for continuous variables and the Chi-square test or Fisher's exact test was used for categorical variables.

BMI, body mass index; DOAC, direct oral anticoagulant; HAS-BLED, hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly; P2Y12, adenosine diphosphate receptor on platelets; IQR, interquartile range; NSAID, nonsteroidal anti-inflammatory drug.

Baseline Characteristics1

Baseline Characteristics¹